ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Acasti Pharma Inc

Acasti Pharma Inc (ACST)

0,58
0,00
( 0,00% )
Aktualisiert: 01:00:00

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,58
Gebot
0,58
Fragen
0,98
Volumen
-
0,00 Tagesbereich 0,00
0,58 52-Wochen-Bereich 0,58
Marktkapitalisierung
Handelsende
0,58
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
9.399.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-2,46
Gewinn pro Aktie (EPS)
-1,37
Erlöse
-
Nettogewinn
-12,85M

Über Acasti Pharma Inc

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Jersey City, New Jersey, USA
Gegründet
-
Acasti Pharma Inc is listed in the Pharmaceutical Preparations sector of the TSX Venture Börse with ticker ACST. The last closing price for Acasti Pharma was $0,58. Over the last year, Acasti Pharma shares have traded in a share price range of $ 0,58 to $ 0,58.

Acasti Pharma currently has 9.399.000 shares in issue. The market capitalisation of Acasti Pharma is $5,45 million. Acasti Pharma has a price to earnings ratio (PE ratio) of -2.46.

ACST Neueste Nachrichten

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a...

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Pharma Reports Second Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a...

Acasti Pharma to Present at Q4 Investor Summit

LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

LAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.580.580.5800CS
4000.580.580.5800CS
12000.580.580.5800CS
26000.580.580.5800CS
52000.580.580.5800CS
156-0.82-58.57142857141.42.30.4739061.49488749CS
260-1.9-76.61290322582.484.050.221056510.89573651CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SCOTScottie Resources Corp
$ 0,99
(500,00%)
1,18k
MMNMonarca Minerals Inc
$ 0,01
(100,00%)
3k
SCLTSearchlight Resources Inc
$ 0,01
(100,00%)
3,3M
TVC.HThree Valley Copper Corp
$ 0,01
(100,00%)
1,5k
RYORio Silver Inc
$ 0,025
(66,67%)
19,54k
MAHMarksmen Energy Inc
$ 0,005
(-50,00%)
1,85M
VPIVitality Products Inc
$ 0,015
(-40,00%)
30k
GKOGeekco Technologies Corporation
$ 0,03
(-40,00%)
100k
VLXVelox Energy Materials Inc
$ 0,08
(-33,33%)
520
ALYAnalytixInsight Inc
$ 0,01
(-33,33%)
25k
SCLTSearchlight Resources Inc
$ 0,01
(100,00%)
3,3M
ALALX Resources Corp
$ 0,03
(20,00%)
2,9M
QNCQuantum Emotion Corp
$ 0,195
(8,33%)
2,33M
FUUF3 Uranium Corp
$ 0,265
(12,77%)
2,08M
MAHMarksmen Energy Inc
$ 0,005
(-50,00%)
1,85M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock